The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.
Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.
